A benefit was also observed for T3 (HR OS = 0.830, 95% CI = 0.688–1.001, p = 0.051) and T4 stages (HR OS = 0.793, 95% CI = 0.627–1.002, p = 0.052) at borderline significance (Table S4 and Figure S4 ).
← all excerpts
The Clinical Relevance of Lymph Node Ratio for Post-Mastectomy Radiotherapy in Triple-Negative Breast Cancer: A Real-World Analysis With Propensity Score Matching Using SEER Database.
1
—
—